Schedule 13G ownership disclosure
Edgewise Therapeutics Inc
Common Stock, $0.0001 par value per share · CUSIP: 28036F105
Event date: 2025-01-27
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Paradigm BioCapital Advisors LP
Shares: 4,738,929.00 · Class: 5.0%
- Paradigm BioCapital Advisors GP LLC
Shares: 4,738,929.00 · Class: 5.0%
- Senai Asefaw, M.D.
Shares: 4,738,929.00 · Class: 5.0%
- Paradigm BioCapital International Fund Ltd.
Shares: 4,181,497.00 · Class: 4.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-008657
- Form type
- SCHEDULE 13G
- Filer
- Edgewise Therapeutics, Inc.
- CIK
- CIK 1710072
- Filed
- Feb 03, 2025
- Reporting period
- Jan 27, 2025
- Description
- Schedule 13G beneficial ownership